Dermapharm Holding Se · XETR:DMP

Dermapharm — Q1 2022 Earnings Presentation

18 slides from Dermapharm's earnings presentation, May 18, 2022

  1. Slide 1: Investors' and Analysts' Conference Call Q1 2022

    INVESTORS’ AND ANALYSTS’ CONFERENCE CALL Q1 2022 Grünwald, 18 Mai 2022

  2. Slide 2: Agenda Q1 2022

    AGENDA Q1 2022 1. Highlights 2022 2. Financial figures Q1 2022 3. Outlook 2022 4. Q&A 2

  3. Slide 3: Highlights

    1 Highlights 3

  4. Slide 4: Highlights 3M 2022

    Highlights 3M 2022 Dermapharm with a good start into the 2022 financial year Continuous growth in Branded Pharmaceuticals Growth drivers in selected therapeutic areas and ongoing vaccine production in Brehna and Reinbek as well as start of “fill & finish” process in Brehna Strengthening of segment H

  5. Slide 5: Financial figures Q1 2022

    2 Financial figures Q1 2022 ———— Fe =. ae Ny ee eee om ee

  6. Slide 6: Dermapharm Group

    Dermapharm Group New growth impulses from latest M&A deals Total Revenue EBITDA1 Significant revenue growth of 9.1% to €m €m, adjusted €231.6m, due to +9.1% 32.4%  vaccine production in cooperation with YoY EBITDA BioNTech SE 231.6 Margin 30.0%  revenue contribution of acquisition Cernelle 212.2 a

  7. Slide 7: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Growth due to the continuous cooperation with BioNTech SE Revenue EBITDA1 Revenue growth of 11.8% to €145.7m, due €m +11.8% €m, adjusted to YoY 47.6%  vaccine production in cooperation with 145.7 EBITDA BioNTech SE 130.3 Margin 45.1%  revenue c

  8. Slide 8: Herbal extracts

    Herbal extracts Growth impulses from latest M&A deals Revenue EBITDA1 Revenue growth of 28.0% to €25.6m, due €m €m, adjusted +28.0% to YoY 27.5%  integration of Cernelle 25.6 EBITDA 20.0 Margin 23.8%  recognition of C3 group as of 1st of February  stable development of Euromed’s extract business

  9. Slide 9: Parallel import business

    Parallel import business Declining market but improved profitability Revenue EBITDA Revenue decreased by 2.4% to €60.4m, €m €m, adjusted -2.4% due to YoY  declining PI market 60.4 2.0% 61.9  continuous growth in the OTC, narcotics EBITDA and medical cannabis could not offset the Margin gap 1.6% 

  10. Slide 10: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increases due to vaccine production and improved financial covenant Earnings before tax (EBT)1  EBT increased by 17.1% to €57.4m €m (unadjusted) resulting in a margin of 24.8% 24.8% EBT Margin 23.1% Mainly influenced by +17.1%  increase of EBITDA YoY 57.4  d

  11. Slide 11: Strong cash flows and cash conversion

    Strong cash flows and cash conversion Dedication to future growth Cash flow and cash conversion1  CF from operating activities mainly €m and in % of Group EBITDA influenced by increased EBT in 3M 2022 59.3% Cash conversion  CF from investing activities reflecting 52.6%  Acquisition of C3  Normal

  12. Slide 12: Balance Sheet of Dermapharm Group

    Balance Sheet of Dermapharm Group Balance sheet as of 31 March 2022  Total assets increased to €1,461m €m (31 December 2021: €1,407m) 1,461 1,461  Non-current assets increased to €957m (31 December 2021: €888m) Equity  Current assets decreased to €504m (31 December 2021: €519m), mainly due to Non

  13. Slide 13: Outlook 2022

    é , Mi 3 Outlook 2022

  14. Slide 14: Outlook 2022: Growth strategy on track

    Outlook 2022 Growth strategy on track – confirming guidance 2022  Growth rates are based on organic growth supported by new launches of in-house developments.  Guidance for the FY 2022 also includes Growth $ growth impulses from M&A deals and the existing cooperation with BioNTech of strategy COVI

  15. Slide 15: Q&A

    4 Q&A 15

  16. Slide 16: Financial calendar

    Financial calendar 2022 Annual Report 2021 CSR Report 2021 Analysts‘ and Half-year Investors‘ Call Annual General Financial Report Quarterly Statement FY 2021 Meeting 2022 as at 30 June 2022 as at 30 September 2022 2022 12 April 1 June 7 September 16 November 22 / 29 March 18 May 23 August 26 Octobe

  17. Slide 17: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat

  18. Slide 18: For information, please contact

    For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 18

Dermapharm Holding — Q1 2022 Earnings Presentation on 6ix